摘要
目的对比盐酸氨酮戊酸外用散光动力疗法及重组人干扰素α2b阴道泡腾片治疗宫颈高危型HPV持续感染相关性疾病的疗效。方法于2019年1月-2020年1月选取于都县人民医院宫颈上皮内病变伴高危型HPV持续感染患者90例,按照随机数字表法分为A、B、C组,每组各30例。A组不做任何处理,B组采用盐酸氨酮戊酸外用散光动力疗法,C组采用重组人干扰素α2b阴道泡腾片治疗。观察3组转阴率和不良反应发生率;T淋巴细胞亚群CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)指标水平和临床疗效。结果B组的转阴率、有效率明显高于A组和C组,差异有统计学意义(P<0.05);3组不良反应发生率无统计学意义(P>0.05);治疗前后3组CD4^(+)/CD8^(+)水平均无显著差异,治疗前3组CD4^(+)、CD8^(+)水平无显著差异,治疗后B、C组CD4^(+)均升高,CD8^(+)均降低,且B组变化幅度更大,差异有统计学意义(P<0.05)。结论盐酸氨酮戊酸外用散光动力疗法在治疗宫颈高危型HPV持续感染方面较重组人干扰素α2b阴道泡腾片更具有优势。
Objective To evaluate the efficacy of amiodarone hydrochloride topical astigmatism dynamic therapy and recombinant human interferonα2B vaginal effervescent tablets in the treatment of cervical high-risk HPV persistent infection related diseases.Methods From January 2019 to January 2020,90 cases of cervical intraepithelial lesions with persistent high-risk HPV infection were selected and randomly divided into group A,group B and group C,30 cases in each group.Group A did not do any treatment,group B was treated with aminolevulinic acid topical astigmatism dynamic therapy,group C was treated with recombinant human interferonα2B vaginal effervescent tablets.The levels of CD4^(+),CD8^(+)and CD8^(+)were observed.Results The negative conversion rate and effective rate of group B were significantly higher than those of group A and group C(P<0.05),but the incidence of adverse reactions in three groups was not statistically significant(P>0.05);Before and after treatment,there was no significant difference in the levels of CD4^(+)/CD8^(+)in the three groups,but there was no significant difference in the levels of CD4^(+)and CD8^(+)in the three groups before treatment.After treatment,CD4^(+)increased and CD8^(+)decreased in groups B and C,and the change range of group B was more significant(P<0.05).Conclusion Amiodarone hydrochloride topical astigmatism dynamic therapy has more advantages than recombinant human interferon alpha 2b vaginal effervescent tablets in the treatment of cervical high-risk HPV persistent infection.
作者
李梅香
邱招秀
肖水英
Li Meixiang;Qiu Zhaoxiu;Xiao Shuiying(The People's Hospital of Yudu County,Yudu,Jiangxi 342300)
出处
《基层医学论坛》
2021年第14期1934-1936,共3页
The Medical Forum
基金
赣州市指导性科技计划项目(GZ2020ZSF597)。